As reported in NPR's article: This experimental drug could change the field of cancer research, a very small group of patients with rectal cancer took a drug called dostarlimab for six months under a trial done by New York's Memorial Sloan Kettering Cancer Center.
"The trial resulted in every single one of their tumors disappearing. The trial group included just 18 people, and there's still more to be learned about how the treatment worked. But some scientists say these kinds of results have never been seen in the history of cancer research."
Dr. Hanna Sanoff of the University of North Carolina's Lineberger Comprehensive Cancer Center joined NPR's All Things Considered to discuss how this drug works and what it could mean for the future of cancer research. She concluded that: "What I'd really like us to do is get a bigger trial where this drug is used in a much more diverse setting to understand what the real, true response rate is going to be. It's not going to end up being 100 percent."
According to Washington Post's Eye-catching cancer drug trial results have researchers asking: What’s next?, "Though the trial was tested in patients whose tumor mutation is present in roughly 4 percent of all cancer cases, the results provide a template for how to tailor immunotherapy drugs to attack specific tumors that, due to their mutation, tend to be more resistant to traditional therapies, according to Julie Gralow, chief medical officer and executive vice president of American Society of Clinical Oncology."
The article about the study is published at NEJM: Improving Treatment Approaches for Rectal Cancer.
No comments:
Post a Comment